Overview of Biomarker-Selected Immune Checkpoint Blockade in Lung Cancer

Download this slideset from Jamie E. Chaft, MD to see a summary of key data on the use of immune checkpoint inhibitor therapy for patients with lung cancer, with information on when IO biomarkers are needed to select optimal therapy.
Jamie E. Chaft, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 4.04 MB
Released: July 9, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Related Content

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for ALL

Renier J. Brentjens, MD, PhD Released: December 3, 2020

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

Frederick L. Locke, MD Released: December 3, 2020

In this slideset from Clinical Care Options, experts provide insights on emerging CAR T-cell strategies for myeloma.

Noopur Raje, MD Released: December 3, 2020

Download this brief slideset for a review of the latest clinical data informing optimal treatment of relapsed ES-SCLC, from Clinical Care Options (CCO)

person default Benjamin Levy, MD Released: December 1, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue